Biocept Statistics
Total Valuation
Biocept has a market cap or net worth of $104. The enterprise value is $4.96 million.
Market Cap | 104 |
Enterprise Value | 4.96M |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Biocept has 1.04 million shares outstanding. The number of shares has increased by 83.94% in one year.
Shares Outstanding | 1.04M |
Shares Change (YoY) | +83.94% |
Shares Change (QoQ) | +76.47% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.00 |
Forward PS | 0.00 |
PB Ratio | 0.00 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 3.66 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.81, with a Debt / Equity ratio of 39.97.
Current Ratio | 1.81 |
Quick Ratio | 1.52 |
Debt / Equity | 39.97 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -156.61 |
Financial Efficiency
Return on equity (ROE) is -411.90% and return on invested capital (ROIC) is -279.08%.
Return on Equity (ROE) | -411.90% |
Return on Assets (ROA) | -104.00% |
Return on Capital (ROIC) | -279.08% |
Revenue Per Employee | $27,120 |
Profits Per Employee | -$612,160 |
Employee Count | 50 |
Asset Turnover | 0.05 |
Inventory Turnover | 11.19 |
Taxes
Income Tax | -125,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -100.00% in the last 52 weeks.
Beta (1Y) | n/a |
52-Week Price Change | -100.00% |
50-Day Moving Average | 0.01 |
200-Day Moving Average | 0.46 |
Relative Strength Index (RSI) | 45.65 |
Average Volume (30 Days) | n/a |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biocept had revenue of $1.36 million and -$30.61 million in losses. Loss per share was -$50.90.
Revenue | 1.36M |
Gross Profit | -14.31M |
Operating Income | -33.16M |
Pretax Income | -30.73M |
Net Income | -30.61M |
EBITDA | -28.14M |
EBIT | -30.54M |
Loss Per Share | -$50.90 |
Balance Sheet
The company has $6.63 million in cash and $11.59 million in debt, giving a net cash position of -$4.96 million or -$4.78 per share.
Cash & Cash Equivalents | 6.63M |
Total Debt | 11.59M |
Net Cash | -4.96M |
Net Cash Per Share | -$4.78 |
Equity / Book Value | 290,000 |
Book Value Per Share | 0.28 |
Working Capital | 3.96M |
Cash Flow
In the last 12 months, operating cash flow was -$17.60 million and capital expenditures -$605,000, giving a free cash flow of -$18.20 million.
Operating Cash Flow | -17.60M |
Capital Expenditures | -605,000 |
Free Cash Flow | -18.20M |
FCF Per Share | -$17.56 |
Margins
Gross margin is -1,055.01%, with operating and profit margins of -2,445.28% and -2,257.23%.
Gross Margin | -1,055.01% |
Operating Margin | -2,445.28% |
Pretax Margin | -2,266.45% |
Profit Margin | -2,257.23% |
EBITDA Margin | -2,075.29% |
EBIT Margin | -2,252.06% |
FCF Margin | -1,342.33% |
Dividends & Yields
Biocept does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -83.94% |
Shareholder Yield | -83.94% |
Earnings Yield | -29,529,323.35% |
FCF Yield | -17,560,531.35% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Biocept has an Altman Z-Score of -23.87 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -23.87 |
Piotroski F-Score | 2 |